A Single-Dose Safety and Tolerability Placebo Controlled Study of Subcutaneous SCH 900222 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Schering-Plough
- 08 Jun 2016 Status changed from recruiting to completed.
- 14 Oct 2009 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.
- 14 May 2009 New trial record